Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease

Industries Profiled:
Biotech; Pharmaceutical


Companies Profiled:
Amgen; Horizon Therapeutics

Study Snapshot

Best Practices, LLC conducted extensive secondary research to examine how Horizon Therapeutics created an ophthalmic blockbuster in a rare disease autoimmune area.

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

• Patient Support Program: Horizon has introduced Patient Access Liaisons who team up with patients and their HCPs to support them throughout the treatment process, including providing assistance with payers.

• The Pandemic Shuts 77% Ophthalmologist Offices:
  • Effect- Tepezza commercialization and administration was hampered.
  • How was it Fixed?- Network of 1,000 infusion centers developed; doctors approached digitally by Tepezza reps; digital marketing and TV advertising.
  • Impact in 2020- 1 Million visits recorded by Tepezza and TED websites; $820M annual revenue recorded by Tepezza (Exceeded projected revenue by 20x)